dc.contributor.author | Medina Moreno, Ana | |
dc.contributor.author | El-Hammadi, Mazen M. | |
dc.contributor.author | Arias Mediano, José Luis | |
dc.date.accessioned | 2023-07-21T08:57:48Z | |
dc.date.available | 2023-07-21T08:57:48Z | |
dc.date.issued | 2023-05-26 | |
dc.identifier.citation | A. Medina-Moreno et al. pH-dependent, extended release and enhanced in vitro efficiency against colon cancer of Tegafur formulated using chitosan-coated poly (ε-caprolactone) nanoparticles. Journal of Drug Delivery Science and Technology 86 (2023) 104594[https://doi.org/10.1016/j.jddst.2023.104594] | es_ES |
dc.identifier.uri | https://hdl.handle.net/10481/83905 | |
dc.description.abstract | Tegafur is used to treat various malignant lesions, including advanced gastric and colorectal cancers. However,
its efficacy is limited by its low oral bioavailability, short half-life and serious toxicity. To address these drawbacks,
a nanoformulation of poly(ε-caprolactone) nanoparticles coated with chitosan was developed for the
delivery of Tegafur. Poly(ε-caprolactone) particles were prepared by an interfacial polymer disposition method,
while surface functionalization with chitosan followed a coacervation procedure. Transmission electron microscopy
and elemental analyses, and electrokinetics of the particles demonstrated that such core/shell nanostructure
was obtained. Compared to unmodified particles, chitosan-coated nanoparticles demonstrated a
substantially increased stability at both 4 and 25 ◦C over 30 days. Particles showed an encapsulation efficiency of
≈64% and a pH-dependent behavior in which complete Tegafur release was extended over 168, 48 or 24 h at pH
7.4 (blood), 6.5 (extracellular microenvironment of tumors) or 5.5 (endosomes/lysosomes of tumor cells),
respectively. Based on hemocompatibility and cell viability tests, chitosan-coated nanoparticles exhibited
satisfactory biocompatibility and safety for drug delivery. Furthermore, Tegafur-loaded chitosan-decorated
particles demonstrated enhanced anticancer efficiency, with half maximal inhibitory concentration values in HT-
29 and T-84 cells of ≈ 4-fold and ≈3.5-fold less than that of the free drug and drug-loaded unmodified nanoparticles,
respectively. In vivo studies are needed to fully assess their efficacy and safety | es_ES |
dc.description.sponsorship | FEDER/Junta de Andalucía – Consejería
de Transformaci´on Econ´omica, Industria, Conocimiento y Universidades,
Spain (Grant P20_00346). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Poly(ε-caprolactone) | es_ES |
dc.subject | Chitosan | es_ES |
dc.subject | Tegafur | es_ES |
dc.subject | Nanoparticles | es_ES |
dc.subject | Colorectal cancer | es_ES |
dc.subject | Drug delivery | es_ES |
dc.title | pH-dependent, extended release and enhanced in vitro efficiency against colon cancer of Tegafur formulated using chitosan-coated poly (ε-caprolactone) nanoparticles | es_ES |
dc.type | journal article | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.identifier.doi | 10.1016/j.jddst.2023.104594 | |
dc.type.hasVersion | VoR | es_ES |